Baidu
map

携手并肩在羊城:重症医学液体复苏研讨会(广州)即将开幕

2019-04-12 小M MedSci原创

2019年4月18日,“重症医学液体复苏研讨会”将于美丽羊城广州召开。

随着基础和临床研究的不断深入,近年来,重症医学取得了长足的进展,而同时,对于一些具体的治疗策略,也涌现出了许多相关的问题与争论。其中,液体复苏就是一个关键的临床问题,为共同讨论和制定更优的液体复苏策略,2019年4月18日,“重症医学液体复苏研讨会”将于美丽羊城-广州召开。该 “重症医学液体复苏研讨会”是系列会议,本次来到羊城广州,邀请到在重症医学领域具有丰富临床经验的专家学者进行研讨并分享自己的宝贵经验。

会议亮点

• 主题分明,结构清晰

会议将分为三个主题,分别为:“脓毒症患者液体复苏策略”、“最佳复苏液体,是否存在?”和“创伤失血患者液体复苏策略”,最后还将包括精彩的主题讨论环节,均为及重症医学液体复苏中面临的重要临床实际问题。

“脓毒症患者液体复苏策略”

脓毒症是重症医学的一个难点,脓毒症的攻克一直是重症医学科医生们追寻的目标。如何制定脓毒症患者液体复苏策略?与会专家学者将从“脓毒症低血容量治疗:4D和4个阶段”、“EGDT,过时了吗?”和“限制性液体复苏,解决之道?”三个方面为大家分析,为大家制定脓毒症患者液体复苏策略提供帮助。

“最佳复苏液体,是否存在?”

复苏液体是保障治疗效果的基石,液体的选择和使用必须基于生理学特性,同时必须考虑其适应症、禁忌症及潜在的毒性作用,以最大程度地提高疗效并减少毒副作用。最佳的复苏液体是晶体液、人工胶体还是白蛋白?本次研讨会将展现最新临床研究和分析,相信大家一定获益匪浅。

“创伤失血患者液体复苏策略”

在失血性休克复苏的过程中需要重建有效循环容量和供氧,从而恢复重要器官灌注,因此创伤失血液体复苏策略尤为重要。如何制定创伤失血患者液体复苏策略?本次研讨会将结合创伤失血的救治原则、失血性休克复苏的目标以及制定液体复苏策略必须面对的问题对创伤失血液体复苏策略进行详细完善的探讨,相信大家一定收获颇丰。

• 大咖云集,博采众长

本次会议邀请的主席及讲者均为国内重症医学领域有深厚学术影响力的专家学者,且均来自临床一线。在重症病人救治与管理,尤其是本次讨论的重点——液体复苏领域具有丰富的临床经验。

大会主席——本次会议荣幸地邀请到了中华医学会重症医学分会主任委员,中山大学附属第一医院重症医学科主任管向东主持全场会议。

————————————————————————————————————

“脓毒症患者液体复苏策略”——将由华中科技大学同济医学院附属协和医院ICU副主任尚游带来;

“最佳复苏液体,是否存在?”——将由中山大学附属第一医院重症医学科专科副主任吴健锋呈现;

 “创伤失血患者液体复苏策略”——将由四川大学华西医院上锦南府分院重症医学科病区主任周琰展示。

会议时间

2019年4月18日(周四)

会议地点

广州远洋宾馆(越秀区环市东路412号)

会议日程



《重症医学液体复苏研讨会》,“南国明珠”广州欢迎你!

更多精彩内容,请关注后续报道!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1994825, encodeId=e82f199482572, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Tue May 07 20:38:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305471, encodeId=98ec13054e144, content=<a href='/topic/show?id=270342e249d' target=_blank style='color:#2F92EE;'>#复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42724, encryptionId=270342e249d, topicName=复苏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d01326, createdName=lizhou0204, createdTime=Sun Apr 14 07:38:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556956, encodeId=513915569564c, content=<a href='/topic/show?id=987a6588307' target=_blank style='color:#2F92EE;'>#液体复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65883, encryptionId=987a6588307, topicName=液体复苏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07bb14837728, createdName=luoxiaog, createdTime=Sun Apr 14 07:38:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579624, encodeId=220615e9624d3, content=<a href='/topic/show?id=1f8b9592e2d' target=_blank style='color:#2F92EE;'>#重症医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95927, encryptionId=1f8b9592e2d, topicName=重症医学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=044b16545174, createdName=ms5906905816781247, createdTime=Sun Apr 14 07:38:00 CST 2019, time=2019-04-14, status=1, ipAttribution=)]
    2019-05-07 kcb069
  2. [GetPortalCommentsPageByObjectIdResponse(id=1994825, encodeId=e82f199482572, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Tue May 07 20:38:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305471, encodeId=98ec13054e144, content=<a href='/topic/show?id=270342e249d' target=_blank style='color:#2F92EE;'>#复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42724, encryptionId=270342e249d, topicName=复苏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d01326, createdName=lizhou0204, createdTime=Sun Apr 14 07:38:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556956, encodeId=513915569564c, content=<a href='/topic/show?id=987a6588307' target=_blank style='color:#2F92EE;'>#液体复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65883, encryptionId=987a6588307, topicName=液体复苏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07bb14837728, createdName=luoxiaog, createdTime=Sun Apr 14 07:38:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579624, encodeId=220615e9624d3, content=<a href='/topic/show?id=1f8b9592e2d' target=_blank style='color:#2F92EE;'>#重症医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95927, encryptionId=1f8b9592e2d, topicName=重症医学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=044b16545174, createdName=ms5906905816781247, createdTime=Sun Apr 14 07:38:00 CST 2019, time=2019-04-14, status=1, ipAttribution=)]
    2019-04-14 lizhou0204
  3. [GetPortalCommentsPageByObjectIdResponse(id=1994825, encodeId=e82f199482572, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Tue May 07 20:38:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305471, encodeId=98ec13054e144, content=<a href='/topic/show?id=270342e249d' target=_blank style='color:#2F92EE;'>#复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42724, encryptionId=270342e249d, topicName=复苏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d01326, createdName=lizhou0204, createdTime=Sun Apr 14 07:38:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556956, encodeId=513915569564c, content=<a href='/topic/show?id=987a6588307' target=_blank style='color:#2F92EE;'>#液体复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65883, encryptionId=987a6588307, topicName=液体复苏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07bb14837728, createdName=luoxiaog, createdTime=Sun Apr 14 07:38:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579624, encodeId=220615e9624d3, content=<a href='/topic/show?id=1f8b9592e2d' target=_blank style='color:#2F92EE;'>#重症医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95927, encryptionId=1f8b9592e2d, topicName=重症医学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=044b16545174, createdName=ms5906905816781247, createdTime=Sun Apr 14 07:38:00 CST 2019, time=2019-04-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1994825, encodeId=e82f199482572, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Tue May 07 20:38:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305471, encodeId=98ec13054e144, content=<a href='/topic/show?id=270342e249d' target=_blank style='color:#2F92EE;'>#复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42724, encryptionId=270342e249d, topicName=复苏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d01326, createdName=lizhou0204, createdTime=Sun Apr 14 07:38:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556956, encodeId=513915569564c, content=<a href='/topic/show?id=987a6588307' target=_blank style='color:#2F92EE;'>#液体复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65883, encryptionId=987a6588307, topicName=液体复苏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07bb14837728, createdName=luoxiaog, createdTime=Sun Apr 14 07:38:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579624, encodeId=220615e9624d3, content=<a href='/topic/show?id=1f8b9592e2d' target=_blank style='color:#2F92EE;'>#重症医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95927, encryptionId=1f8b9592e2d, topicName=重症医学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=044b16545174, createdName=ms5906905816781247, createdTime=Sun Apr 14 07:38:00 CST 2019, time=2019-04-14, status=1, ipAttribution=)]

相关资讯

Crit Care Med:液体复苏对提高重症脓毒症患儿预后有影响吗?

为评估液体复苏是否对重症脓毒症患儿预后是否改善,本研究采取前瞻性观察研究方法对数量较大的官方数据库进行研究。

Lancet Respir Med:使用羟乙基淀粉进行液体复苏,不划算

对危重患者进行液体复苏时,羟乙基淀粉 vs 晶体液的解决方案,并不能改善以病人为中心的短期结局;那么其对长期健康经济结果又有什么影响呢? 我们对来自CHEST队列的参与者进行了预先设定的成本效益分析,这些参与者随机分为6%羟乙基淀粉+分子量约为130 kD,或摩尔替换率为0·4或0·9%的氯化钠(生理盐水)进行液体复苏治疗。临床结果是6个月和24个月时的死亡和获得生命年;6个月时的健康相关生

瞿洪平:脓毒症液体复苏:宜“早”“足”“湿”

脓毒症患者需要液体复苏,但大量液体输入有液体蓄积的风险,进而可能导致严重后果。于是,面对脓毒症患者,是否补液?怎么补液?补多少?补什么?已成为重症监护病房(ICU)医生需要慎重思量的问题。在前不久召开的第七次全国重症医学大会上,举办了两场辩论,分别就脓毒症是否需要液体复苏,以及复苏时是否用胶体进行了讨论。在脓毒症早期,足量的液体复苏可改善患者预后,减少之后的液体需求及进一步脏器损伤,而并不显著

Intensive Care Med:严重感染和感染性休克:液体复苏模式与结局

严重感染和感染性休克最初几小时液体复苏的最佳模式存在争议,积极或保守均有推荐。2017年5月,发表在《Intensive Care Med》的一项研究调查了严重感染和感染性休克输液模式与结局。

Baidu
map
Baidu
map
Baidu
map